Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
JSON
Savulescu C, Prats-Uribe A, Brolin K, Uusküla A, Bergin C, Fleming C, Zvirbulis V, Zavadska D, Szułdrzyński K, Gaio V, Popescu CP, Craiu M, Cisneros M, Latorre-Millán M, Lohur L, McGrath J, Ferguson L, Abolina I, Gravele D, Machado A, Florescu SA, Lazar M, Subirats P, Clusa Cuesta L, Sui J, Kenny C, Krievins D, Barzdina EA, Melo A, Kosa AG, Miron VD, Muñoz-Almagro C, Milagro AM, Bacci S, Kramarz P, Nardone A, VEBIS HCW Study Group
Vaccine 45 (-) 126615 [2025-01-25; online 2024-12-25]
Repeated COVID-19 booster vaccination was recommended in healthcare workers (HCWs) to maintain protection. We measured the relative vaccine effectiveness (rVE) of the second booster dose of COVID-19 vaccine compared to the first booster, against laboratory-confirmed SARS-CoV-2 infection in HCWs. In a prospective cohort study among HCWs from 12 European hospitals, we collected nasopharyngeal or saliva samples at enrolment and during weekly/fortnightly follow-up between October 2022 and May 2023. We estimated rVE of the second versus first COVID-19 vaccine booster dose against SARS-CoV-2 infection, overall, by time since second booster and restricted to the bivalent vaccines only. Using Cox regression, we calculated the rVE as (1-hazard ratio)*100, adjusting for hospital, age, sex, prior SARS-CoV-2 infection and at least one underlying condition. Among the 979 included HCWs eligible for a second booster vaccination, 392 (40 %) received it and 192 (20 %) presented an infection during the study period. The rVE of the second versus first booster dose was -5 % (95 %CI: -46; 25) overall, 3 % (-46; 36) in the 7-89 days after receiving the second booster dose. The rVE was 11 % (-43; 45) when restricted to the use of bivalent vaccines only. The bivalent COVID-19 could have reduced the risk of SARS-CoV-2 infection among HCWs by 11 %. However, we note the limitation of imprecise rVE estimates due to the proportion of monovalent vaccine used in the study, the small sample size and the study being conducted during the predominant circulation of XBB.1.5 sub-lineage. COVID-19 vaccine effectiveness studies in HCWs can provide important evidence to inform the optimal timing and the use of updated COVID-19 vaccines.
PubMed 39724693
DOI 10.1016/j.vaccine.2024.126615
Crossref 10.1016/j.vaccine.2024.126615
pii: S0264-410X(24)01297-0